JAK2 and myeloid neoplasm: Currently, two JAK inhibitors have been approved for myeloid malignancies: Ruxolitinib (JAK1/JAK2 inhibitor) for the treatment of primary and secondary MF, and hydroxyurea resistant PV, and fedratinib (JAK2 inhibitor) for PMF.